Skip to main content
BAXBaxter International Inc.Sell4.4·$21.04+4.68%
BAX · Concentration risk · 10-K extracted

Baxter International (BAX) concentration risks

Updated

The most significant concentration Baxter International discloses is single source suppliers, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Source: Baxter International’s SEC Form 10-K filed view the filing on SEC EDGAR ↗

At a glance

Disclosed-size breakdown · 3 disclosed concentrations

HIGH1
MEDIUM2
LOW0
Disclosed concentrations

Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).

HIGHOutside partySupplier

single source suppliers

10-K Item 1: 'certain of these materials are secured from single source suppliers or on a spot basis and not pursuant to a contractual arrangement'
SEC 10-K · filed Feb 2026
MEDIUMOutside partyCustomer

GPOs, IDNs, and certain other distributors

10-K Item 1A: 'Segments of our business are significantly dependent on major contracts with GPOs, IDNs, and certain other distributors and purchasers'
SEC 10-K · filed Feb 2026
MEDIUMOutside partySupplier

Cardinal Health and Medline

10-K Item 1: 'third parties, such as Cardinal Health, Inc. and Medline Inc., warehouse and ship a significant portion of our products through their distribution centers'
SEC 10-K · filed Feb 2026
TrendMatrix Research · concentration synthesis

What these concentrations mean together

updated 2026-06-24

The company's disclosed concentration profile combines a supply-side dependency with two customer and distribution channel dependencies, creating a profile where both ends of the value chain carry moderate or high-share concentration risks. On the supply side, certain materials are secured from single-source suppliers or purchased on a spot basis without a formal contractual arrangement — a high-share dependency by disclosed size. For a medical products company with a broad portfolio of hospital and renal care supplies, single-source inputs that lack contractual protection represent a meaningful operational risk, since a supplier disruption or price increase cannot be absorbed through contract terms or quickly redirected to a qualified alternative. The customer side adds two moderate-share dependencies. First, segments of the business are significantly dependent on major contracts with group purchasing organizations, integrated delivery networks, and certain other distributors and purchasers — a structural and dependency mix, as these large healthcare procurement entities control access to a substantial portion of hospital purchasing. Second, Cardinal Health, Inc. and Medline Inc. warehouse and ship a significant portion of products through their distribution centers — a moderate-share operational dependency on third-party logistics that, if disrupted, would affect product availability at the point of care. Together these exposures indicate a business that is leveraged at both the input and distribution ends to a small number of critical counterparties. The most acute single-point risk is the uncontracted single-source supply exposure; the distribution dependency on Cardinal Health and Medline is similarly concentrated but reflects standard healthcare supply chain architecture.

For the engine’s reasoning on BAX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Industry peers · Medical Instruments & Supplies

Peer concentration profile

SymbolNameHIGHMEDIUMLOWTotal
BLCOBausch + Lomb Corporation2002
BAXBaxter International Inc.1203
ATRAptarGroup, Inc.1102
BDXBecton, Dickinson and Company1102
ALGNAlign Technology, Inc.1001
AVTRAvantor, Inc.1001

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.

Concentration disclosures are extracted verbatim from SEC 10-K filings; the disclosed-size classification and the synthesis above are engine-derived. Size reflects how large each exposure is against fixed share thresholds (HIGH >50%, MEDIUM 25–50%, LOW <25% or an explicit diversification statement), not a judgment of how dangerous it is, and is not a buy/sell rating, a price target, or a view on the stock. Not a complete list of risk factors — see the full filing.

Home Stocks BAX Concentration risk